 |

Two River Group Holdings, LLC is an independent New York based venture capital firm that specializes in building biotechnology and pharmaceutical companies. The Two River team has significant experience building companies to develop novel human therapeutic technologies to address a broad range of diseases, including oncology, infectious disease, Central Nervous System disorders, cardiology and dermatology.
Two River's goal is to create a limited number of high quality companies, each having a pipeline of clinical and preclinical compounds that address a common therapeutic area. To achieve this goal, the Two River team conducts rigorous clinical, legal and financial due diligence on hundreds of technologies each year, choosing only a select few to acquire for commercial development.
Once a technology is acquired, the Two River team has the comprehensive skills required to run a developmental stage biotechnology company, including an in-depth knowledge of clinical trial design, regulatory pathways, chemistry manufacturing control, intellectual property management and effective clinical trial execution.
Two River then recruits a highly skilled management team with a combination of drug development experience and leadership excellence for each portfolio company. These leading minds are drawn from both academia and industry, often with prior experience as senior management in large pharmaceutical or leading biotechnology companies.
In addition, Two River is able to provide its portfolio companies with access to financial markets. Two River's affiliate, Riverbank Capital Securities, Inc., through its global network of investors, is able to assist portfolio companies in obtaining financing without receiving cash or equity commissions, so that 100% of the proceeds are used by the company to develop its compounds.
Two River believes that our highly selective approach to acquiring technologies, together with our operational capabilities and access to capital helps to ensure the greatest opportunity for the success of each of our portfolio companies.
 |
 |